John Sterling

Novartis’ $23 billion investment in U.S.-based infrastructure over the next five years is designed to increase manufacturing capacity.

The Biomanufacturing Excellence Act creates a national Center of Excellence to drive innovation in biopharmaceutical manufacturing.

The Biomanufacturing Excellence Act creates a national Center of Excellence to drive innovation in biopharmaceutical manufacturing.

Starting in 2026, NIBRT training will be piloted at Heartland BioWorks’ Indianapolis headquarters with hands-on training beginning in 2027.

Starting in 2026, NIBRT training will be piloted at Heartland BioWorks’ Indianapolis headquarters with hands-on training beginning in 2027.

AAV-SLB101 is a rationally designed capsid developed for enhanced skeletal muscle, cardiac tropism, and reduced biodistribution to the liver.

Berry Genomics plans to expand its sequencing capability to clinical assays like congenital adrenal hyperplasia and spinal muscular atrophy.

Researchers now know that MS starts way earlier than the clinical onset, creating the real possibility that MS could one day be controlled.

The peptide lab is designed to produce a range of molecules, including linear peptides, cyclic peptides, and peptide-drug conjugates.

Firefly users will gain access to optimized, ready-to-run methods developed by application teams at SPT Labtech and 10X Genomics.

Mytos Launches Automated CDMO for Manufacturing Stem-Cell Derived Therapies

A major challenge in AAV gene therapy has been developing scalable, cost-efficient processes to reliably produce high-quality vectors.

Around 5,000 Americans are diagnosed with ALS each year. About half of patients die within 14 to 18 months of being diagnosed.

In July 2025 Symbiosis manufactured its 1,000th sterile batch, marking over 14 years of support for biopharma clients.

Lonza will manufacture RION's PEP™ drug substance at its manufacturing facility in Houston, Texas.

Deeper levels of multi-omics analysis are increasingly important for understanding complex biology, according to Ultima Genomics.

Andelyn and Tern Therapeutics Partner on Gene Therapy Manufacturing

BioMADE’s investment in Iowa is expected to provide access to the technology infrastructure required to determine if a product is commercially viable.

The new facility will be Asahi Kasei Life Science's fourth spinning plant for hollow-fiber cellulose membrane filters.

The Waltham Innovation Center will complement Aldevron’s established scientific teams in Fargo, ND, and Madison, WI.